Please wait while the formulary information is being retrieved.
EMPLICITI (ELOTUZUMAB)
- Multiple myeloma
300 mg intravenous solution
- Infuse 10 mg/kg at a rate not to exceed 5 ml/min by intravenous routeevery 2 weeks
400 mg intravenous solution
- Infuse 10 mg/kg at a rate not to exceed 5 ml/min by intravenous routeevery 2 weeks
Multiple myeloma
- Infuse 10 mg/kg at a rate not to exceed 2 ml/min by intravenous routeevery 2 weeks
- Infuse 10 mg/kg at a rate not to exceed 5 ml/min by intravenous routeevery 2 weeks
- Infuse 20 mg/kg at a rate not to exceed 5 ml/min by intravenous routeevery 4 weeks
- Infuse 10 mg/kg at a rate not to exceed 5 ml/min by intravenous routeevery 2 weeks on days 1 and 15 of a 28 day treatment cycle
- Infuse 10 mg/kg at a rate not to exceed 5 ml/min by intravenous routeonce weekly on days 1, 8, 15 and 22 of a 28-day cycle (cycles 1 and 2)
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Abnormal hepatic function tests
- Pregnancy
Severe
Moderate
- Herpes zoster
- Severe infection
EMPLICITI (ELOTUZUMAB)
- Multiple myeloma
- Hyperkalemia
- Hypocalcemia
- Infection
- Leukopenia
- Opportunistic fungal infection
- Pneumonia
- Thrombocytopenic disorder
- Anorexia
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Hyperglycemia
- Peripheral neuropathy
- Pharyngitis
- Upper respiratory infection
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Anemia
- Bradycardia
- Cataracts
- Hypertension
- Hypotension
- Lymphopenia
- Pulmonary thromboembolism
- Bone pain
- Chills
- Dyspnea
- Headache disorder
- Limb pain
- Mouth irritation
- Muscle spasm
- Peripheral edema
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute renal failure
- Hypersensitivity drug reaction
- Hypesthesia
Less Severe
- Chest pain
- Mood changes
- Night sweats
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Elotuzumab
No pediatric safety and efficacy established.
- 1 Day – 18 Years
- No pediatric safety and efficacy established.
Elotuzumab
- Severity Level:
D
- Additional Notes: Based on drug pharmacology possible risk of dev tox
Contraindicated
Elotuzumab
Potential for serious adverse outcomes, manufacturer does not recommend
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential for serious adverse outcomes, manufacturer does not recommend |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Multiple myeloma | |
C90.0 | Multiple myeloma |
C90.00 | Multiple myeloma not having achieved remission |
C90.02 | Multiple myeloma in relapse |
0-9 | A-Z |
---|---|
C90.0 | Multiple myeloma |
C90.00 | Multiple myeloma not having achieved remission |
C90.02 | Multiple myeloma in relapse |
Formulary Reference Tool